Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant ROS1-targeted therapy plus endocrine therapy in invasive lobular breast cancer
2019-004942-14Phase 2Completed
- Sponsor
- Institut Jules Bordet
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of entrectinib in Invasive Lobular Carcinoma (ILC), sponsored by Institut Jules Bordet. Primary endpoint: Residual cancer burden 0/1. Started Oct 2020; status: completed.
02
Drugs
entrectinib
03
Conditions
Invasive Lobular Carcinoma (ILC)
Beyond the preview
Go deeper on 2019-004942-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004942-14.